ProQR Therapeutics N.V.
PRQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentoā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.22
Price+0.45%
$0.01
1Y
Price
Market Cap
$233.864m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-303.2%
EBITDA Margin-319.1%
Net Profit Margin-301.3%
Free Cash Flow MarginRevenue
$16.486m
-12.8%
1y CAGR+79.6%
3y CAGR+109.2%
5y CAGREarnings
-$39.671m
-42.9%
1y CAGR+5.0%
3y CAGR+2.5%
5y CAGREPS
-$0.43
-26.5%
1y CAGR+12.6%
3y CAGR+10.8%
5y CAGRBook Value
$66.983m
$137.537m
Assets$70.554m
Liabilities$16.862m
DebtDebt to Assets
12.3%
-0.5x
Debt to EBITDAFree Cash Flow
-$42.948m
-13.6%
1y CAGR-57.3%
3y CAGR-83.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company